0.00Open0.35Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover0.00%IV5.47%PremiumJan 17, 2025Expiry Date0.28Intrinsic Value100Multiplier-5DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.66Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Coherus BioSciences Stock Discussion
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Wednesday, 22nd January at 7:00 am
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate –
– Antitumor activity was observed across both viral and non-viral etiologies –
– Data support continued...
$Coherus BioSciences (CHRS.US)$
$Coherus BioSciences (CHRS.US)$
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
7 minutes ago, 4:00 AM PST
Via GlobeNewswire
CHRS
Share
- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor -
- Proceeds to fund development of key combination programs with LOQTORZI, including casdozokitug, a first-in-class, cli...
No comment yet